Refractory Angina Market Size, Share, Trend, Epidemiology & Market Forecast to 2030

Refractory Angina Market Size, Share, Trend, Epidemiology & Market Forecast to 2030

Delveinsight Business Research
DelveInsight’s “Refractory Angina Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Refractory Angina, historical and forecasted epidemiology as well as the Refractory Angina market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Refractory Angina (RA) is a chronic condition where pain remains persistent for the duration of less than or equal to 3 months, characterized by angina. Angina is a type of chest pain caused by reduced blood flow to the heart. Angina has two types, chronic or stable angina and unstable angina. Around 10–15% of patients of Chronic Angina meet the measures of RA. The clinical load of RA is growing rapidly due to an ageing population and improved Coronary Artery Disease (CAD).

Symptoms of RA are chest pain, shortness of breath, and easy fatigability. RA also shows neurological, psychogenic and mitochondrial dysfunctions in addition to tissue ischemia which are responsible for an insistent cardiac pain. These symptoms cause poor self-perceived health status, high incidence of depression, and burden to the health care system due to significant resource utilization.

The Refractory Angina market report covers emerging drugs, current treatment practices, Refractory Angina market share of the individual therapies, current and forecasted Refractory Angina Market Size from 2017 to 2030 segmented by seven major markets. The report also provides detailed current Refractory Angina treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. 

Refractory Angina Market Key Facts

  • The European Society of Cardiology report (2002), estimated that 5–10% of all people with angina have Refractory Angina.

  • According to the study titled “Current strategies for the prevention of angina in patients with stable coronary artery disease” by Ami B et al., in the US, approximately 4–14% of the chronic Angina patients with chronic angina meet the criteria for Refractory Angina.

  • According to the European Society of Cardiology (ESC) guidelines titled “Current strategies for the prevention of angina in patients with stable coronary artery disease” by Fox K. et al., the prevalence of angina increase sharply with the age in both genders from 0.1–1% in women aged between 45–54 to 10–15% in women aged 65–74 and 2–5% in men aged 45–54 to 10–20% in men aged 65–74.

 refractory angina

Visit For Sample Pages:


Key Benefits of Refractory Angina Market Report

Refractory Angina market report provides an in-depth analysis of Refractory Angina Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.

The Refractory Angina market report will help in developing business strategies by understanding the Refractory Angina Market trends & developments, key players and future market competition that will shape and drive the Refractory Angina market in the upcoming years.

The Refractory Angina market report covers Refractory Angina current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.

The report provides a detailed assessment of the Refractory Angina market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. 


Refractory Angina Market

The Refractory Angina market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Refractory Angina market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology. 

 The report gives a thorough detail of Refractory Angina market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. 


Refractory Angina Epidemiology

The Refractory Angina epidemiology section covers insights about historical and current Refractory Angina patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

 It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  


Refractory Angina Drugs Uptake and Key Market Players

Refractory Angina Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Refractory Angina market or expected to get launched in the market during the study period. The analysis covers Refractory Angina market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. Several emerging pharmacotherapies for  Refractory Angina are in different stages of clinical development which include BCDA-02 (BioCardia), Ad5FGF-4 (Angionetics/Huapont Life Sciences), CLBS14 (Caladrius Biosciences), and several others.


Table of Content

1. Key Insights

2. Executive Summary 

3. Refractory Angina Competitive Intelligence Analysis

4. Refractory Angina Market Overview at a Glance

5. Refractory Angina Disease Background and Overview

6. Refractory Angina Patient Journey

7. Refractory Angina Epidemiology and Patient Population

8. Refractory Angina Treatment Algorithm, Current Treatment, and Medical Practices

9. Refractory Angina Unmet Needs

10. Key Endpoints of Refractory Angina Treatment

11. Refractory Angina Marketed Products

12. Refractory Angina Emerging Therapies

13. Refractory Angina Seven Major Market Analysis

14. Attribute Analysis

15. Refractory Angina Market Outlook (7 major markets)

16. Refractory Angina Access and Reimbursement Overview

17. KOL Views on the Refractory Angina Market.

18. Refractory Angina Market Drivers

19. Refractory Angina Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer


About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.


Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States